08:00 , Dec 23, 2013 |  BC Week In Review  |  Company News

Depomed, Nautilus Neurosciences sales and marketing update

Depomed gained U.S. rights to Cambia diclofenac oral solution for migraines from Nautilus. Nautilus will receive $48.7 million in cash up front and will be eligible for up to $5 million in milestones on net...
02:02 , Dec 19, 2013 |  BC Extra  |  Company News

Depomed jumps on U.S. acquisition of migraine drug

Depomed Inc. (NASDAQ:DEPO) jumped $1.47 (18%) to $9.82 on Wednesday after announcing late Tuesday that it gained U.S. rights to migraine drug Cambia diclofenac oral solution from Nautilus Neurosciences Inc. (Bedminster, N.J.). Nautilus will receive...
08:00 , Nov 4, 2013 |  BC Week In Review  |  Clinical News

Nexodyn regulatory update

Applied Pharma Research said it received CE Mark approval for its Nexodyn to manage acute and chronic wounds. Nexodyn is a super-oxidized electrolyzed aqueous solution. The company said it expects to launch the product in...
08:00 , Jan 21, 2013 |  BC Week In Review  |  Company News

MonoSol Rx, Vestiq deal

Vestiq acquired exclusive, U.S. rights to Zuplenz ondansetron oral soluble film from MonoSol. MonoSol received an undisclosed upfront payment and is eligible for double-digit royalties. Zuplenz is approved to prevent nausea and vomiting associated with...
07:00 , Oct 15, 2012 |  BC Week In Review  |  Company News

Stellar Pharmaceuticals sales and marketing update

Stellar and its Tribute Pharmaceuticals operating division launched Cambia diclofenac oral solution in Canada to treat acute migraine headaches with or without aura in adults. The wholesale price for a nine-dose pack is C$89.10 ($91)....
07:00 , Apr 2, 2012 |  BC Week In Review  |  Clinical News

Cambia diclofenac regulatory update

Health Canada approved Cambia diclofenac from Stellar's Tribute Pharmaceuticals subsidiary for the acute treatment of migraine attacks with or without aura in adults. The company plans to launch the product next half. FDA approved Cambia...
08:00 , Mar 5, 2012 |  BC Week In Review  |  Clinical News

Zolmitriptan oral dispersible film regulatory update

Applied Pharma said Germany and 14 other EU member states approved an MAA for zolmitriptan oral dispersible film to treat migraine. The product was approved via the decentralized procedure, with Germany acting as the reference...
01:54 , Mar 2, 2012 |  BC Extra  |  Company News

Oral film formulation of zolmitriptan approved in EU

Applied Pharma Research S.A. (Balerna, Switzerland) said Germany and 14 other EU member states approved an MAA for zolmitriptan oral dispersible film to treat migraine. The product was approved via the decentralized procedure, with Germany...
08:00 , Jan 23, 2012 |  BC Week In Review  |  Company News

Norgine, Applied Pharma Research sales and marketing update

Applied Pharma Research granted Norgine commercialization rights to Setofilm ondansetron in Europe and certain countries in the Middle East, Africa, and Australasia. Setofilm is a dissolving oral film strip formulation of ondansetron using RapidFilm technology...
07:00 , Jul 18, 2011 |  BC Week In Review  |  Company News

MonoSol Rx, Par Pharmaceutical sales and marketing update

MonoSol reacquired from Par's Strativa Pharmaceuticals subsidiary U.S. rights to Zuplenz ondansetron oral soluble film. In 2008, Par acquired exclusive, U.S. commercialization rights to the selective serotonin (5-HT3) receptor antagonist, which is formulated using MonoSol's...